The majority of prostate cancers (CaP) are detected in early stages with uncertain prognosis. Therefore, an intensive effort is underway to define early predictive markers of CaP with aggressive progression characteristics. CONCLUSIONS: In summary, we propose that evaluation of SPARC in primary CaP has potential as a prognostic marker of metastatic progression.
Introduction
The lifetime risk of getting prostate cancer (CaP) in the USA is 1 in 6, but only about 1 in 34 will die of CaP, 1 partially because early stage organ-confined CaP is usually curable. However, more aggressive CaP and recurrent cases may progress to hormone-refractory metastasis, which remains non-curable. 2 Therefore, identification of prognostic indicators of disease progression is one of the high-priority areas in CaP research and is the objective of this study.
CaP transcriptome evaluations have identified consistent tumor-specific gene expression alterations as promising diagnostic bio-markers (GSTP1, PCA3, AMACR and ERG). [3] [4] [5] [6] [7] [8] More recently, gene fusions involving androgenregulated promoters and ETS-related transcription factors or RAF kinases were discovered as promising CaP-specific bio-markers and therapeutic targets. 9, 10 RAF fusions are present in about 2% of CaP associated with aggressive disease. 10 Earlier, other genes such as p53, [11] [12] [13] AR, 14, 15 AKT/PTEN, 16 EZH2, 17 SPINK, 18 ETV1 9, 19 have been shown to be associated with subsets of progressive CaP, however their use as prognostic markers in clinical setting needs to be streamlined. SPARC (secreted protein, acidic, rich in cysteine) is a secreted glycoprotein that supports the migration of CaP cells to bone and demonstrates increased expression in CaP metastatic foci and cell lines. 20 Increased expression of SPARC has been associated with increased metastatic potential and poor outcome in several malignancies. 21 Previous studies reported that SPARC was expressed in prostate tissue and more prominently in metastatic foci. SPARC protein is expressed in luminal cells, basal cells and fibromuscular stromal cells. The SPARC gene (also known as osteonectin or BM-40) is mapped to chromosome 5q31.3 and linked to bone metastasis. 22 The sequence is highly conserved between species and codes for a 32 000-dalton secreted matrix-associated glycoprotein. SPARC plays an important role in cell-matrix interactions, tissue remodeling, wound repair, cellular differentiation, morphogenesis, cell migration and angiogenesis. 21, [23] [24] [25] In this study, the transcriptome of laser capture-microdissected tumor cells with poorly differentiated (PD) and with well differentiated (WD) phenotype were analyzed for gene expression and biochemical pathway alterations significantly associated with aggressive CaP. SPARC, a gene linked to bone metastasis, was identified as a potential early marker of less favorable outcome associated with poor differentiation of CaP. Further validation at protein level revealed that high SPARC expression at the time of radical prostatectomy (RP) is associated with an increased risk of tumor metastasis.
Materials and methods

Tissue laser capture micro-dissection and GeneChip analysis
Prostate tissue specimens were obtained under an Institutional Review Board-approved protocol from patients treated by RP at Walter Reed Army Medical Center. Three cohorts were selected: (1) a discovery cohort of 40 patients for GeneChip analysis (20 with welland 20 with PD tumor cells); (2) a validation cohort of 110 patients for quantitative reverse transcriptase-PCR (QRT-PCR) analysis (Supplementary Table S1 ); (3) and an independent cohort of 53 patients to validate our hypothesis on the prognostic value of SPARC protein expression, where matched patients did (N ¼ 26) or did not (N ¼ 27) develop metastasis within the mean followup time of 78.8 months (Supplementary Table S2) .
Prostate tumor cells were microdissected from optimum cutting temperature-embedded and hematoxylin-and eosin-stained frozen prostate sections of RP specimens. 6 Total RNA was isolated from the tissue laser capture micro-dissected samples with the Micro-RNA kit (Stratagene, La Jolla, CA, USA) and quantified using RiboGreen dye (Molecular Probes, Eugene, OR, USA) and VersaFluor fluorimeter (BioRad, Hercules, CA, USA). 6, 26 RNA amplification (Ribo AMP version C, Arcturus, Mountain View, CA, USA) and GeneChip (HG U133 Plus 2.0, Affymetrix, Santa Clara, CA, USA) analysis was performed according to the manufacturer's instructions. 
QRT-PCR
Bioinformatics analysis
A 40 GeneChip dataset obtained from the analysis of 20 patients with WD and 20 patients with PD tumors were processed for GeneChip data analyses by the ChipInspector software (Genomatix Software, Munich, Germany). Affymetrix chip CEL files with the expression values of single probes of the microarray experiment were analyzed. [27] [28] [29] Importantly, the Genomatix platform applies probe-by-probe analysis, rather than averaging predefined probe sets for a given locus, in order to improve the signal-to-noise ratio, to increase the statistical stringency and to eliminate probe mismatches or multiple matches. 30, 31 The program also corrects annotation errors, and combines GeneChip data analysis with pathway, promoter and literature analysis. [27] [28] [29] [30] [31] Expression values from all validated probes were collected by ChipInspector with significant changes in expression with a false discovery rate of 0%. Transcripts representing significant expression changes were then determined by mapping each single probe of the chip to the human genome and transcript annotation (NCBI). Mismatching or multiple matching probes were eliminated. Perfect matching probes were SPARC expression predicts metastasis CA DeRosa et al annotated to their correct transcripts, resulting in the retrieval of significantly expressed transcripts with a minimum probe coverage of three per transcript as a standard parameter. The knowledge-based BiblioSphere software (Genomatix Software) was used for regulatory network mining and functional classification. 29 Expressed transcripts were matched to genes resulting in differentially expressed genes. Applying the MeSH filter 'Disease' for functional classification and the category 'Prostatic Neoplasias' the relevant network was identified.
The GeneChip dataset has been submitted to Gene Expression Omnibus database (accession GSE32448), a public functional genomics data repository supporting MIAME-compliant data submission. The dataset, including raw CEL data, is packaged and submitted consistent with the MIAME guidelines/checklist. Below is a list of critical elements regarding MIAME compliance provided to Gene Expression Omnibus database at data submission: raw data for each hybridization (CEL files); processed (normalized) data for the set of hybridizations; essential sample annotation including experimental factors and their values; experimental design including sample-data relationships; sufficient annotation of the array; essential laboratory and dataprocessing protocols.
Statistical analysis
Clinical and pathological characteristics of the study sample were examined including age at time of surgery, diagnostic PSA (ng ml À1 ), race (Caucasian and other vs African American), CaP family history (yes vs no, first-and second-degree relatives), pathological T stage (pT2 vs pT3), Gleason sum (2-6, 7, vs 8-10), margin status (positive vs negative), PSA recurrence (yes vs no), and follow-up time. PSA recurrence was defined as two consecutive post-operative PSA X0.2 ng ml À1 2 months after surgery. Frequencies were reported for categorical patient features whereas measures of central tendency and dispersion are reported for continuous patient features. Wilcoxon or Kruskal-Wallis tests were used to test the association of SPARC mRNA expression levels with clinical or pathological characteristics. Kaplan-Meier unadjusted survival analysis was used to examine time to PSA recurrence across the median of SPARC mRNA expression. Multivariate Cox proportional hazards analysis was used to identify factors, including SPARC mRNA expression, that are independently associated with odds of PSA recurrence over time.
In IHC assays, the SPARC positivity was measured in four categories (1: o25%, 2: 25-50%, 3:51-75% and 4: 475%), and the SPARC intensity was measured in three categories (1: weak, 2: moderate and 3: strong). SPARC score was calculated as SPARC positivity multiplied with SPARC intensity, so SPARC score has values of 1, 2, 3, 4, 6, 8, 9 and 12. Chi-square or Fisher's exact tests were used to evaluate the association of SPARC intensity, positivity or score with metastasis status. Logistic regression was used to report the sensitivity, specificity and AUC of SPARC score for predicting metastasis.
Statistical analyses were performed with the SAS package (SAS Institute, Cary, NC, USA). Po0.05 was considered statistically significant.
Results
Expression of SPARC predicts aggressive form of CaP
GeneChip data generated from prostate tumor cells of 40 hormone-naïve CaP patients, 20 with PD and 20 with WD tumors, were analyzed by ChipInspector and BiblioSphere softwares. A total of 8370 genes were expressed in PD and WD tumor cells and subsequent analysis of genes overexpressed in PD tumor cells in comparison with WD tumor cells highlighted a group of 31 genes using a prostate neoplasia filter (Figure 1) . A seven-gene network clustered around SPARC was then defined by co-citation and/or biochemical function analyses. To assess the regulatory regions of genes within the network, we performed promoter retrieval by using the Gene2Promoter software (Genomatix Software
Genes in the network code for various types of collagens, such as, COL1A1 (Gene ID: 1277), COL1A2 (Gene ID: 1278) and COL3A1 (Gene ID: 1281). In addition, an extracellular phospholipase: PLA2G2A (Gene ID: 5320), a transcription factor: MAFB (Gene ID: 9935), that has a role in lineage specification in hematopoiesis, and the extracellular seleno-glycoprotein SEPP1 (Gene ID: 6414) clusters around the central regulatory node, SPARC (Gene ID: 6678). The NKXH_NKXH_HOX composite model was identified within the upstream regions of COL1A2, COL3A1, SEPP1 and SPARC genes suggesting that osteogenesis may be a common theme of the regulation mediated by the NKXH_NKXH_HOX composite model.
We further evaluated and validated the association of NKXH_NKXH_HOX regulatory model in PD prostate tumor cells. Genome-wide analysis identified this regulatory model in 3146 non-redundant promoters of which 947 overlapped with 8370 expressed genes in our data set of WD and PD tumors cells (Figure 1 ). This is a remarkable enrichment, as finding such an overlap by chance is highly unlikely (P ¼ 1.3e
À112
). Comparative analyses of these 947 genes between PD and WD tumor cells along with evaluation by the knowledge-based pathway-analysis software BiblioSphere revealed a 12-gene network upregulated in PD tumors with the SPARC gene in the central regulatory node (Figure 2a) . This network had a definite association with bone tissue (6 of the 12 genes), which is a common site of CaP metastasis.
The 12-member gene network is formed by ABCC5: ATP-binding cassette, sub-family C, member 5 (Gene ID: 10057); COL1A2: collagen, type I, alpha 2 (Gene ID: 1278); COL3A1: collagen, type III, alpha 1 (Gene ID: 1281); HOXC4: homeobox C4 (Gene ID: 3221); HOXC6: homeobox C6 (Gene ID: 3223); IGFBP3: insulin-like growth factor binding protein 3 (Gene ID: 3486); MME: membrane metallo-endopeptidase (Gene ID: 4311); SPARCL1: SPARC-like 1 (hevin) (Gene ID: 8404); RGS5: regulator of G-protein signaling 5 (Gene ID: 8490); SEPP1: selenoprotein P, plasma, 1 (Gene ID: 6414); TSPAN5: tetraspanin 5 (Gene ID: 10098) and in the center of the network SPARC: secreted protein, acidic, rich in cysteine (osteonectin) (Gene ID: 6678).
Real-time QRT-PCR confirmed the GeneChip data and revealed higher SPARC expression in PD compared with (Table 1 ). Higher expression of SPARC in PD as opposed to WD tumors was validated, increased expression in higher grade tumors (Gleason 8-9) was also significant. Kaplan-Meier unadjusted survival analysis (N ¼ 110) did not show a significant decrease in PSA recurrence-free survival of patients with higher SPARC mRNA expression across median split groups (P ¼ 0.2335) (Supplementary Figure 1) . We noted that in multivariate Cox proportional hazard model, when adjusted for other clinico-pathological variables such as race, pathological stage and grade, SPARC mRNA expression did not show independent prediction value on PSA recurrence-free survival (P ¼ 0.3678) (Supplementary Table S3 ).
High SPARC protein expression in CaP is associated with an increased risk of tumor metastasis
Our results from GeneChip analysis and quantitative evaluation of SPARC mRNA expression in 110 CaP patients are consistent with the literature that indicates a role for SPARC, 22, 23 and a high expression of SPARC protein 20 , in metastasis. Therefore, we hypothesized that high SPARC expression (likely at protein level as SPARC is functionally linked to metastasis) in primary prostate tumors may predict a higher chance of later metastasis. To test our hypothesis, a cohort of 53 patients treated with RP was selected for SPARC expression analysis (Supplementary Table S2 ). Of the 53 patients, 26 developed metastasis (13 in bone and 13 in lymph nodes), the other 27 did not (see Methods/IHC). The two groups of CaP patients were matched for Gleason grade and for pathological stage. SPARC protein expression in Figure 1 Strategy for the delineation of a biochemical network associated with poorly differentiated prostate cancers (CaP). Bioinformatics analysis steps are depicted in consecutive text boxes, actions in green and results in blue. PD, poorly differentiated; WD, well differentiated.
SPARC expression predicts metastasis CA DeRosa et al the primary tumors was determined by IHC in FFPE tissue sections of whole-mounted prostates obtained from RP. The analysis revealed that high SPARC protein expression at the time of prostatectomy, either by percentage of positive staining (P ¼ 0.0064), or by staining intensity (P ¼ 0.0118), was associated with the development of future metastasis ( Table 2 ). The combination of the percentage and intensity in a SPARC score (defined in Methods) demonstrated a further increased significance (P ¼ 0.0006, Table 2 ). The receiver-operating characteristic analysis of SPARC score (AUC ¼ 0.803, Figure 3 , Supplementary Table S4) supported our hypothesis on the predictive value of SPARC.
Discussion
In this study, a combination of comparative global and focused gene-expression measurements between PD and WD prostate tumor cells, along with knowledgebased analyses and transcription-regulatory mechanism centered bioinformatics, highlighted association of a biochemical network of 12 genes with SPARC gene as a central node with PD phenotype. Of note, there was conservation of NKXH_NKXH_HOX composite regulatory elements in the promoters of the genes in this network suggestive of the biological significance of this gene-expression regulatory mechanism in CaP progression. As SPARC has a role 22, 23 and high protein levels 20 in metastasis, we hypothesized that high SPARC expression in primary tumor may predict future metastasis. Indeed, further analysis revealed that high SPARC protein expression in malignant prostate cells at the time of RP is associated with an increased risk of tumor metastasis (see study flow chart in Supplementary  Figure 2) .
It has been reported that SPARC was expressed in prostate tissue, especially strongly in metastatic CaP. 20 Elevated expression of SPARC has been associated with increased metastatic potential in other malignancies. 21 However, the association highlighted here between future metastasis and SPARC expression in primary tumor has not been described in CaP. The biological functions of SPARC reported in various malignancies, including important roles in cell migration, cell-matrix 13, 37, 38 and more recently B-RAF fusions were identified in about 2% of CaP which associated with aggressive disease, 10 but these findings have yet to be incorporated in clinical setting. These observations may either reflect the heterogeneity of progressive disease or may suggest the need for novel approaches to identify early prognostic markers.
In summary, this study revealed a network of genes with common regulatory elements that associate with PD primary prostate tumors. Importantly, SPARC was identified as a central node in this gene network. SPARC is a secreted glycoprotein that supports the migration of CaP cells to bone, a major site of CaP metastasis. This study, along with previous reports showing high expression of SPARC in metastatic CaP, underscore the potential of SPARC in predicting metastatic progression and warrants further evaluations of SPARC in combination with either other emerging prognostic markers or traditional prognostic nomogram. 
